Julia Aulin1, Agneta Siegbahn2, Ziad Hijazi1, Michael D Ezekowitz3, Ulrika Andersson4, Stuart J Connolly5, Kurt Huber6, Paul A Reilly7, Lars Wallentin1, Jonas Oldgren8. 1. Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Sweden. 2. Uppsala Clinical Research Center and Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden. 3. Lankenau Institute for Medical Research and the Heart Center, Wynnewood, PA, USA. 4. Uppsala Clinical Research Center, Uppsala University, Sweden. 5. Population Health Research Institute, Hamilton, Canada. 6. 3rd Department of Internal Medicine Cardiology and Emergency Medicine, Vienna, Austria. 7. Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT, USA. 8. Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Sweden. Electronic address: Jonas.oldgren@ucr.uu.se.
Abstract
BACKGROUND: Inflammation has been associated with cardiovascular disease and the burden of atrial fibrillation (AF). In this study we evaluate inflammatory biomarkers and future cardiovascular events in AF patients in the RE-LY study. METHODS:Interleukin-6 (IL-6), C-reactive protein (CRP) (n = 6,187), and fibrinogen (n = 4,893) were analyzed at randomization; outcomes were evaluated by Cox models and C-statistics. RESULTS: Adjusted for clinical risk factors IL-6 was independently associated with stroke or systemic embolism (P = .0041), major bleedings (P = .0001), vascular death (P < .0001), and a composite thromboembolic outcome (ischemic stroke, systemic embolism, myocardial infarction, pulmonary embolism and vascular death) (P < .0001). CRP was independently related to myocardial infarction (P = .0047), vascular death (P = .0004), and the composite thromboembolic outcome (P = .0001). When further adjusted for cardiac (troponin and N-terminal fragment B-type natriuretic peptide [NT-proBNP]) and renal (cystatin-C) biomarkers on top of clinical risk factors IL-6 remained significantly related to vascular death (P < .0001), major bleeding (P < .0170) and the composite thromboembolic outcome (P < .0001), and CRP to myocardial infarction (.0104). Fibrinogen was not associated with any outcome. C-index for stroke or systemic embolism increased from 0.615 to 0.642 (P = .0017) when adding IL-6 to the clinically used CHA2DS2-VASc risk score with net reclassification improvement of 28%. CONCLUSION: In patients with AF, IL-6 is related to higher risk of stroke and major bleeding, and both markers are related to higher risk of vascular death and the composite of thromboembolic events independent of clinical risk factors. Adjustment for cardiovascular biomarkers attenuated the prognostic value, although IL-6 remained related to mortality, the composite of thromboembolic events, and major bleeding, and CRP to myocardial infarction.
RCT Entities:
BACKGROUND: Inflammation has been associated with cardiovascular disease and the burden of atrial fibrillation (AF). In this study we evaluate inflammatory biomarkers and future cardiovascular events in AFpatients in the RE-LY study. METHODS:Interleukin-6 (IL-6), C-reactive protein (CRP) (n = 6,187), and fibrinogen (n = 4,893) were analyzed at randomization; outcomes were evaluated by Cox models and C-statistics. RESULTS: Adjusted for clinical risk factors IL-6 was independently associated with stroke or systemic embolism (P = .0041), major bleedings (P = .0001), vascular death (P < .0001), and a composite thromboembolic outcome (ischemic stroke, systemic embolism, myocardial infarction, pulmonary embolism and vascular death) (P < .0001). CRP was independently related to myocardial infarction (P = .0047), vascular death (P = .0004), and the composite thromboembolic outcome (P = .0001). When further adjusted for cardiac (troponin and N-terminal fragment B-type natriuretic peptide [NT-proBNP]) and renal (cystatin-C) biomarkers on top of clinical risk factors IL-6 remained significantly related to vascular death (P < .0001), major bleeding (P < .0170) and the composite thromboembolic outcome (P < .0001), and CRP to myocardial infarction (.0104). Fibrinogen was not associated with any outcome. C-index for stroke or systemic embolism increased from 0.615 to 0.642 (P = .0017) when adding IL-6 to the clinically used CHA2DS2-VASc risk score with net reclassification improvement of 28%. CONCLUSION: In patients with AF, IL-6 is related to higher risk of stroke and major bleeding, and both markers are related to higher risk of vascular death and the composite of thromboembolic events independent of clinical risk factors. Adjustment for cardiovascular biomarkers attenuated the prognostic value, although IL-6 remained related to mortality, the composite of thromboembolic events, and major bleeding, and CRP to myocardial infarction.
Authors: Adomas Bunevicius; Andrius Radziunas; Sarunas Tamasauskas; Arimantas Tamasauskas; Edwards R Laws; Giorgio Iervasi; Robertas Bunevicius; Vytenis Deltuva Journal: J Neurooncol Date: 2018-02-19 Impact factor: 4.130
Authors: Edna Maria Vissoci Reiche; Jair Roberto Gelinksi; Daniela Frizon Alfieri; Tamires Flauzino; Marcio Francisco Lehmann; Maria Caroline Martins de Araújo; Marcell Alysson Batisti Lozovoy; Andrea Name Colado Simão; Elaine Regina Delicato de Almeida; Michael Maes Journal: Metab Brain Dis Date: 2019-03-14 Impact factor: 3.584
Authors: Brent T Mausbach; Gabrielle Decastro; Carlos Vara-Garcia; Taylor C Bos; Roland von Känel; Michael G Ziegler; Joel E Dimsdale; Matthew A Allison; Paul J Mills; Thomas L Patterson; Sonia Ancoli-Israel; Christopher Pruitt; Igor Grant Journal: Psychosom Med Date: 2019-09 Impact factor: 3.864